How should I manage a 22-year-old patient with a history of cannabis-induced psychosis 4 months ago, who is currently taking brexpiprazole 3 mg, mirtazapine 30 mg nightly, zolpidem (Lunesta) 1 mg nightly for sleep, and clonazepam 0.25 mg daily, and remains depressed without hallucinations?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Management of Persistent Depression Following Cannabis-Induced Psychosis

Optimize the antidepressant therapy by increasing mirtazapine to 45 mg nightly or switching to a different antidepressant class, while maintaining brexpiprazole 3 mg and tapering off clonazepam and eszopiclone (Lunesta).

Current Medication Assessment

Your patient's regimen requires several adjustments:

  • Brexpiprazole 3 mg: This is appropriate and should be continued. The dose is within therapeutic range for psychosis management, and brexpiprazole has demonstrated efficacy in patients with schizophrenia spectrum disorders regardless of substance use comorbidity 1. The absence of hallucinations indicates good control of positive symptoms.

  • Mirtazapine 30 mg: This is a suboptimal dose for major depression. Mirtazapine's antidepressant efficacy typically requires 45 mg daily due to increased noradrenergic activity at higher doses. At 30 mg, you're primarily getting sedation and antihistamine effects without maximal antidepressant benefit.

  • Eszopiclone (Lunesta) 1 mg + Clonazepam 0.25 mg daily: This combination is problematic. You're using two sedative-hypnotics when mirtazapine at proper dosing should address sleep. The FDA label warns that eszopiclone can cause complex behaviors, amnesia, and worsening depression 2. Benzodiazepines like clonazepam carry dependence risk and can worsen depression long-term.

Recommended Treatment Algorithm

Step 1: Address the Depression (Primary Issue)

Option A - Optimize Current Regimen:

  • Increase mirtazapine to 45 mg nightly
  • This addresses both depression and sleep without additional sedative-hypnotics
  • Monitor for 4-6 weeks for response

Option B - Switch Antidepressant:

  • If mirtazapine optimization fails or side effects are problematic, switch to an SSRI (sertraline 50-200 mg or escitalopram 10-20 mg) or SNRI (venlafaxine XR 75-225 mg)
  • These have better evidence for depression in psychotic disorders when combined with antipsychotics

Step 2: Taper Unnecessary Sedatives

  • Discontinue eszopiclone immediately - it's redundant with mirtazapine and carries risks of behavioral changes and depression worsening 2
  • Taper clonazepam over 2-4 weeks - reduce by 0.125 mg every 5-7 days to avoid withdrawal
  • Benzodiazepines were appropriate for acute agitation in cannabis-induced psychosis 3, 4 but have no role 4 months out

Step 3: Continue Antipsychotic Maintenance

  • Maintain brexpiprazole 3 mg - this is appropriate for preventing psychotic relapse
  • Current guidelines recommend continuing the same antipsychotic that achieved symptom control 5
  • Brexpiprazole specifically shows efficacy in substance use disorder populations and may reduce cannabis craving if relapse occurs 1

Critical Diagnostic Consideration

At 4 months post-cannabis-induced psychosis, you must reassess the diagnosis. Recent meta-analysis shows that 20% of cannabis-induced psychosis cases convert to schizophrenia spectrum disorder 6. The persistent depression with resolved psychosis suggests:

  1. Primary depressive episode (most likely given symptom pattern)
  2. Negative symptoms of emerging schizophrenia (less likely without cognitive/functional decline)
  3. Bipolar depression (5% conversion rate from cannabis-induced psychosis 6)

Key differentiating features to assess:

  • Functional impairment pattern (pervasive vs. episodic)
  • Cognitive symptoms (concentration, memory, executive function)
  • Anhedonia severity and quality
  • Family history of mood vs. psychotic disorders
  • Presence of subsyndromal psychotic symptoms

Cannabis Abstinence Monitoring

Verify continued abstinence - even occasional cannabis use significantly increases risk of:

  • Conversion to schizophrenia spectrum disorder (20% baseline risk 6)
  • Persistent hopelessness and depression (31-35% mediation effect 7)
  • Psychotic relapse (HR 4.32 with combined depression and cannabis use 7)

Timeline for Reassessment

  • 2 weeks: Assess tolerability of medication changes
  • 4-6 weeks: Evaluate antidepressant response (50% symptom reduction is adequate response)
  • 12 weeks: If inadequate response, consider switching antidepressant class or augmentation strategies
  • 6 months: Reassess need for continued antipsychotic if no psychotic symptoms recur and cannabis abstinence maintained

Common Pitfalls to Avoid

  1. Don't continue polypharmacy with sedatives - mirtazapine alone should manage sleep
  2. Don't undertreate the depression - 30 mg mirtazapine is insufficient
  3. Don't prematurely discontinue brexpiprazole - maintain for at least 12 months post-psychosis per guidelines 8, 5
  4. Don't assume this is just residual psychosis - the symptom pattern (depression without hallucinations) indicates a mood disorder component requiring specific treatment

The evidence strongly supports addressing the depression as the primary therapeutic target while maintaining antipsychotic prophylaxis and eliminating unnecessary sedative-hypnotics.

Related Questions

A patient with cannabis-induced psychosis is taking brexpiprazole (Rexulti) 2 mg, which has improved paranoia and psychosis but still has significant anxiety; what non‑benzodiazepine anxiolytic can be added?
In a patient with cannabis‑induced psychosis stabilized on brexpiprazole (Rexulti) 3 mg for about three weeks, with no recent psychosis but worsening depression while taking mirtazapine 30 mg at bedtime, should the brexpiprazole dose be increased to 4 mg now or should more time be allowed at the current dose?
Can I add Gabapentin (Neurontin) for sleep and anxiety issues related to cannabis use?
Is it safe to smoke cannabis after stopping lurasidone (Latuda) for 12 days?
In a patient with recurrent depressive episodes and a single manic episode with psychotic features requiring hospitalization that occurred during heavy cannabis use, how can substance‑induced bipolar I disorder be distinguished from primary bipolar I disorder?
What is the appropriate fluid choice and management for a patient with hypochloremia (serum chloride 91.2 mmol/L) given normal sodium and potassium levels?
What further testing is indicated for a 46-year-old woman with self‑resolving palpitations over the past three days?
In a patient with a solitary kidney, is dose adjustment of ciprofloxacin required?
What oral medications are effective for pruritus without a visible rash?
How should I evaluate and manage a patient with an isolated elevated free T3 level while free T4 and TSH are normal?
What is the appropriate management for a 75-year-old asymptomatic woman with mild normocytic anemia (hemoglobin 11.6 g/dL, mean corpuscular volume 80.8 fL, mean corpuscular hemoglobin 25.8 pg, red cell distribution width 16 %), low white‑blood‑cell count (3.0 ×10⁹/L), borderline neutropenia (absolute neutrophil count 1.42 ×10⁹/L), mild monocytosis, and poikilocytosis/ovalocytosis on peripheral smear?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.